Jessica Mendoza

Novo's corporate headquarters outside of Copenhagen is even designed to mimic the winding structure of an insulin molecule. The company is also uniquely Danish in its corporate structure.

So Novo Nordisk, the company, is overseen by the nonprofit Novo Nordisk Foundation. And it's the foundation that decides how to reinvest some of the company's profits.

So Novo Nordisk, the company, is overseen by the nonprofit Novo Nordisk Foundation. And it's the foundation that decides how to reinvest some of the company's profits.

So Novo Nordisk, the company, is overseen by the nonprofit Novo Nordisk Foundation. And it's the foundation that decides how to reinvest some of the company's profits.

Novo's corporate structure effectively means that its CEO has to answer to the foundation. And since 2017, Novo's CEO has been Lars Juergensen.

Novo's corporate structure effectively means that its CEO has to answer to the foundation. And since 2017, Novo's CEO has been Lars Juergensen.

Novo's corporate structure effectively means that its CEO has to answer to the foundation. And since 2017, Novo's CEO has been Lars Juergensen.

And what was his tenure like?

And what was his tenure like?

And what was his tenure like?

Well, I see Novo Nordisk putting up the biggest gains.

Well, I see Novo Nordisk putting up the biggest gains.

Well, I see Novo Nordisk putting up the biggest gains.

Ozempic launched in the U.S. in 2018, just about a year after Jorgensen took over as CEO. The drug is approved for treating diabetes, but people quickly realized that the weekly doses didn't just help control blood sugar. They could help control weight. And that's when Ozempic really took off.

Ozempic launched in the U.S. in 2018, just about a year after Jorgensen took over as CEO. The drug is approved for treating diabetes, but people quickly realized that the weekly doses didn't just help control blood sugar. They could help control weight. And that's when Ozempic really took off.

Ozempic launched in the U.S. in 2018, just about a year after Jorgensen took over as CEO. The drug is approved for treating diabetes, but people quickly realized that the weekly doses didn't just help control blood sugar. They could help control weight. And that's when Ozempic really took off.

Ozempic and Wegovy are what's known as GLP-1s, now one of the most successful drug categories in the industry. Novo's biggest challenger in the space is an American company, one that it's competed with for something like a century, Eli Lilly.

Ozempic and Wegovy are what's known as GLP-1s, now one of the most successful drug categories in the industry. Novo's biggest challenger in the space is an American company, one that it's competed with for something like a century, Eli Lilly.

Ozempic and Wegovy are what's known as GLP-1s, now one of the most successful drug categories in the industry. Novo's biggest challenger in the space is an American company, one that it's competed with for something like a century, Eli Lilly.

What did that look like post-ozempic?